Cargando…
cMYC expression in thyroid follicular cell-derived carcinomas: a role in thyroid tumorigenesis
BACKGROUND: cMYC regulates approximately 15% of human genes and is involved in up to 20% of all human cancers. Reports discussing cMYC protein expression in thyroid carcinomas are limited, with controversies pertaining to cMYC expression patterns noted in the literature. The aims of the current stud...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627435/ https://www.ncbi.nlm.nih.gov/pubmed/28974238 http://dx.doi.org/10.1186/s13000-017-0661-0 |
_version_ | 1783268715870027776 |
---|---|
author | Sakr, Hany I. Chute, Deborah J. Nasr, Christian Sturgis, Charles D. |
author_facet | Sakr, Hany I. Chute, Deborah J. Nasr, Christian Sturgis, Charles D. |
author_sort | Sakr, Hany I. |
collection | PubMed |
description | BACKGROUND: cMYC regulates approximately 15% of human genes and is involved in up to 20% of all human cancers. Reports discussing cMYC protein expression in thyroid carcinomas are limited, with controversies pertaining to cMYC expression patterns noted in the literature. The aims of the current study were to clarify patterns and intensities of cMYC expression in follicular cell-derived thyroid carcinomas across a spectrum of cancer morphologies and disease aggressivities, to correlate cMYC with BRAF(V600E) expression, and to evaluate the potential role of cMYC in progression of well-differentiated thyroid carcinomas into less well-differentiated carcinomas. METHODS: Immunohistochemical studies using specific monoclonal antibodies for cMYC and BRAF(V600E) were performed on tissue microarrays built from follicular cell-derived thyroid carcinomas (25 papillary, 24 follicular, 24 oncocytic variant of follicular, and 21 undifferentiated). In addition, cMYC IHC testing was also performed on whole tissue tumor sections from a subset of patients. Nodular hyperplasia cases were used as non-neoplastic controls. Appropriate positive and negative controls were included. RESULTS: cMYC was expressed almost exclusively in a nuclear fashion in both thyroid carcinomas and nodular hyperplasias. cMYC expression was weakly positive in both nodular hyperplasias and well-differentiated carcinomas. The majority of undifferentiated carcinomas (UDCs) showed strong nuclear cMYC positivity. PTC cases that were positive for cMYC (6/25) harbored the BRAF (V600E) mutation. A correlation was confirmed between cMYC intensity and tumor size in UDCs. UDC cases that developed out of well-differentiated thyroid carcinomas showed frank overexpression of cMYC in the undifferentiated tumor components. CONCLUSIONS: Our study suggests that nuclear overexpression of cMYC correlates with tumorigenesis / dedifferentiation in follicular cell derived thyroid carcinomas, a concept that has not been shown before on whole tissue sections. |
format | Online Article Text |
id | pubmed-5627435 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-56274352017-10-12 cMYC expression in thyroid follicular cell-derived carcinomas: a role in thyroid tumorigenesis Sakr, Hany I. Chute, Deborah J. Nasr, Christian Sturgis, Charles D. Diagn Pathol Research BACKGROUND: cMYC regulates approximately 15% of human genes and is involved in up to 20% of all human cancers. Reports discussing cMYC protein expression in thyroid carcinomas are limited, with controversies pertaining to cMYC expression patterns noted in the literature. The aims of the current study were to clarify patterns and intensities of cMYC expression in follicular cell-derived thyroid carcinomas across a spectrum of cancer morphologies and disease aggressivities, to correlate cMYC with BRAF(V600E) expression, and to evaluate the potential role of cMYC in progression of well-differentiated thyroid carcinomas into less well-differentiated carcinomas. METHODS: Immunohistochemical studies using specific monoclonal antibodies for cMYC and BRAF(V600E) were performed on tissue microarrays built from follicular cell-derived thyroid carcinomas (25 papillary, 24 follicular, 24 oncocytic variant of follicular, and 21 undifferentiated). In addition, cMYC IHC testing was also performed on whole tissue tumor sections from a subset of patients. Nodular hyperplasia cases were used as non-neoplastic controls. Appropriate positive and negative controls were included. RESULTS: cMYC was expressed almost exclusively in a nuclear fashion in both thyroid carcinomas and nodular hyperplasias. cMYC expression was weakly positive in both nodular hyperplasias and well-differentiated carcinomas. The majority of undifferentiated carcinomas (UDCs) showed strong nuclear cMYC positivity. PTC cases that were positive for cMYC (6/25) harbored the BRAF (V600E) mutation. A correlation was confirmed between cMYC intensity and tumor size in UDCs. UDC cases that developed out of well-differentiated thyroid carcinomas showed frank overexpression of cMYC in the undifferentiated tumor components. CONCLUSIONS: Our study suggests that nuclear overexpression of cMYC correlates with tumorigenesis / dedifferentiation in follicular cell derived thyroid carcinomas, a concept that has not been shown before on whole tissue sections. BioMed Central 2017-10-03 /pmc/articles/PMC5627435/ /pubmed/28974238 http://dx.doi.org/10.1186/s13000-017-0661-0 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Sakr, Hany I. Chute, Deborah J. Nasr, Christian Sturgis, Charles D. cMYC expression in thyroid follicular cell-derived carcinomas: a role in thyroid tumorigenesis |
title | cMYC expression in thyroid follicular cell-derived carcinomas: a role in thyroid tumorigenesis |
title_full | cMYC expression in thyroid follicular cell-derived carcinomas: a role in thyroid tumorigenesis |
title_fullStr | cMYC expression in thyroid follicular cell-derived carcinomas: a role in thyroid tumorigenesis |
title_full_unstemmed | cMYC expression in thyroid follicular cell-derived carcinomas: a role in thyroid tumorigenesis |
title_short | cMYC expression in thyroid follicular cell-derived carcinomas: a role in thyroid tumorigenesis |
title_sort | cmyc expression in thyroid follicular cell-derived carcinomas: a role in thyroid tumorigenesis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627435/ https://www.ncbi.nlm.nih.gov/pubmed/28974238 http://dx.doi.org/10.1186/s13000-017-0661-0 |
work_keys_str_mv | AT sakrhanyi cmycexpressioninthyroidfollicularcellderivedcarcinomasaroleinthyroidtumorigenesis AT chutedeborahj cmycexpressioninthyroidfollicularcellderivedcarcinomasaroleinthyroidtumorigenesis AT nasrchristian cmycexpressioninthyroidfollicularcellderivedcarcinomasaroleinthyroidtumorigenesis AT sturgischarlesd cmycexpressioninthyroidfollicularcellderivedcarcinomasaroleinthyroidtumorigenesis |